Lexeo Therapeutics (NASDAQ:LXEO) outlined its approach to evaluating LX2020, an investigational AAVrh10-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, or ACM, ahead of an expected clinical and regulatory update later this quarter. CEO Nolan Townsend said PKP2 ACM is a serious, progressive genetic heart disease with no approved therapies designed to modify its course. The company […]